帕利哌酮缓释片与齐拉西酮片治疗精神分裂症的对照研究  

A Comparative Study of Paliperidone Sustained-release Tablets and Ziprasidone Tablets for Schizophrenia

作　　者：董苒[1] 高昕[1] 陆恩光[1] 张京华[1] 葛红敏[1] 崔鹏[1] 杨会增[1] 韩冬昱[1] 

机构地区：[1]天津市安定医院一科,300222

出　　处：《职业与健康》2011年第24期2943-2944,共2页Occupation and Health

摘　　要：目的探讨帕利哌酮缓释片与齐拉西酮片治疗精神分裂症的疗效和安全性。方法将60例精神分裂症患者随机分为帕利哌酮研究组30例和齐拉西酮对照组30例,各观察8周。分别与治疗前和治疗1、2、4和8周采用阳性与阴性症状量表(PANSS)评价其疗效。通过体检、实验室检查、心电图检查及其他不良事件的收集评价其安全性。结果研究组显效率和有效率分别为73.3%和86.7%,对照组分别为70.0%和80.0%,2组之间差异无统计学意义(P>0.05)。2组不良反应率比较,差异无统计学意义(P>0.05),不良反应均较轻。结论帕利哌酮缓释片治疗精神分裂症疗效与齐拉西酮相当。[ Objective] To study the efficacy and safety of paliperidone sustained-release tablets and ziprasidone tablets for schizophrenia. [ Methods]60 patients with schizophrenia were randomly divided into the study group [ paliperidone, 30 cases） and the control group [ ziprasidone, 30 cases ） , and two groups were observed for 8 weeks. The efficacy was assessed by positive and negative symptom scale （ PANSS） before and at the end of 1, 2, 4 and 8 weeks of treatment respectively. The safety was evaluated by physical examination, laboratory examination, electrocardiogram examination and collecting other adverse events. [ Results ] The obvious effective rate and effective rate of the study group was 73.3% and 86.7% , that of the control group was 70.0% and 80.0% respectively, and there was no significant difference between two groups （ P 〉 0.05 ）. The adverse reactions of two groups were mild, and the difference in incidence of adverse reactions between two groups was not significant [ P 〉 0. 05 ）. [ Conclusion ] Paliperidone sustained-release tablets and ziprasidone tablets have similar effect on schizophrenia.

关 键 词：帕利哌酮 齐拉西酮 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]